| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
An antibiotic produced by Streptomyces fradiae. [PubChem] |
| Indication |
For the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis. |
| Pharmacology |
Fosfomycin is a broad spectrum antibiotic that concentrates in kidney and bladder and is used to treat uncomplicated urinary tract infections. Fosfomycin also reduces nephrotoxicity and ototoxicity of platinum-containing anti-tumor agents. |
| Toxicity |
LD50>5 g/kg (rats). Side effects may include diarrhea |
| Affected Organisms |
| • |
Enteric bacteria and other eubacteria |
|
| Biotransformation |
No transformation, excreted unchanged |
| Absorption |
Fosfomycin tromethamine is rapidly absorbed following oral administration and converted to fosfomycin. Oral bioavailability under fasting conditions is 37%. When given with food, oral bioavailability is reduced to 30% |
| Half Life |
5.7 (± 2.8) hours. The elimination half-life is 40 hours in anuric patients undergoing hemodialysis. |
| Protein Binding |
0% (not bound to plasma proteins) |
| Elimination |
Fosfomycin is excreted unchanged in both urine and feces. |
| Distribution |
* 136.1 ±44.1 L |
| Clearance |
* 16.9 +/- 3.5 L/hr |
| External Links |
|